PrimeVax Immuno-Oncology

Primevax is leveraging powerful immuno-stimulatory properties of the dengue virus to prime the human body to fight late-stage cancers. Primevax is a clinical stage immuno-oncology company developing novel therapies for cancer. We are pioneering the world’s first use of the Dengue Virus as an oncolytic virotherapy to address late stage failed treatment markets. Primevax has patented the world’s only cancer treatment using dengue virus. We are privileged to be working with our esteemed collaboration partners:. We believe that the dengue virus presents a new method to invoke a strong anti-cancer immune response while demonstrating a high safety profile. Our lead asset PV001-DV, is a live, attenuated strain of Dengue Virus. In recognizing this attractive anti-cancer profile, Primevax signed an exclusive license with the U.S.